Company news
Claritas Pharmaceuticals Inc. (OTC:CLAZF) news
Claritas Pharmaceuticals Inc. news releases on 6ix. Latest, Jan 26, 2018: Kalytera Announces Issuance of Shares under Services Agreement with The Salzman…
Press releases — page 3
Kalytera Announces Issuance of Shares under Services Agreement with The Salzman Group of Israel
January 26, 2018
Kalytera Announces Settlement of Debt Transaction
January 11, 2018
Kalytera Announces Approval of Shares for Services and Settlement of Debt Transaction with The Salzman Group of Israel
December 22, 2017
Kalytera Therapeutics, Inc. Announces Closing of Brokered Private Placement
December 20, 2017
Kalytera Announces Initiation of Phase 2 Clinical Study in Prevention of Graft Versus Host Disease and Agreement with The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team
December 7, 2017
Kalytera Announces Second US Patent for Prevention and Treatment of Graft Versus Host Disease
November 27, 2017
Kalytera Announces $5 Million Private Placement of Convertible Debenture Units
November 22, 2017
Kalytera Announces Notice of Allowance of US Patent for Treatment of Graft Versus Host Disease
November 15, 2017
Kalytera Therapeutics, Inc. Announces Robert Farrell, J.D. as CEO; Additional Board and Management Changes
October 10, 2017
Kalytera Receives IRB Approval for Proposed Phase 2 Study Evaluating CBD in the Prevention of Graft versus Host Disease
September 7, 2017
Kalytera Reports Second Quarter 2017 Financial Results
August 31, 2017
Kalytera Submits Phase 2 Study Protocol to IRBs for Cannabidiol in the Prevention of Graft versus Host Disease
August 14, 2017
Kalytera Reports First Quarter 2017 Financial Results
May 31, 2017
Kalytera Announces Changes to its Board of Directors
May 26, 2017
Kalytera Reports FY 2016 Results; Provides Corporate Update and 2017 Outlook
May 2, 2017
Kalytera Identifies Sites for Planned GvHD Clinical Trials; Company’s Research Gains Support at EBMT 2017
April 25, 2017
OTC Markets Group Welcomes New OTCQB Companies – April 20
April 20, 2017
Kalytera Applies for $5 Million R&D Grant from IIA
April 17, 2017
Kalytera Therapeutics Appoints Pini Ben-Elazar to Board of Directors
March 17, 2017